Correction: Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals

• Reem El-Shenawy,
• Rehab I. Moustafa,
• Naiera M. Helmy,
• Yasmine S. El-Abd,
• Ashraf A. Tabll,
• Yasser K. Elesnawy,
• Heba Shawky

Affiliations

Reem El-Shenawy

Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre

Rehab I. Moustafa

Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre

Naiera M. Helmy

Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre

Yasmine S. El-Abd

Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre

Ashraf A. Tabll

Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre

Yasser K. Elesnawy

National Committee for Control of Viral Hepatitis (NCCVH), Ministry of Health and Population

Heba Shawky

Therapeutic Chemistry Department, Pharmaceutical Industries and Drug Research Institute, National Research Centre